Speaking at a Wall Street Journal event during the World Economic Forum in Davos, Pfizer CEO Albert Bourla publicly denounced Robert F. Kennedy Jr.’s vaccine positions as “anti-science,” characterizing them as ideological rather than data-driven. Bourla noted that while discussions on cancer research and drug pricing with Kennedy have been fruitful, dialogue breaks down once vaccines are introduced. When pressed on what it would take to advance immunization policy, he bluntly stated that the U.S. Department of Health and Human Services needed new leadership, implying that the current administration’s top health official is an impediment to constructive vaccine strategy.

Bourla warned that recent reductions in federal support for university research threaten America’s preeminence in life sciences. He highlighted that elite U.S. institutions—historically dominant in global health research—have ceded roughly 80% of top-tier rankings to Chinese universities. He cited improvements in China’s intellectual property regime and regulatory modernization as catalysts for a “meteoric” expansion of original pharmaceutical research, urging Western governments to strengthen domestic competitiveness instead of attempting to restrict China’s scientific advances.

Despite near-term patent expirations on blockbuster drugs such as Eliquis and Ibrance, Pfizer’s forward price-to-earnings ratio has fallen below 9, while its annualized dividend yield stands at approximately 6.7%. Management forecasts full-year revenue of $59.5 billion to $62.5 billion, a decline from the prior year’s $62 billion. Critics view the stock as a potential value trap given anticipated revenue headwinds and elevated R&D spending. Supporters counter that strategic acquisitions—such as the 2023 purchase of Seagen and the recent Metsera deal to enter the GLP-1 market—position Pfizer for renewed growth and justify the current low valuation.